2. Academic Validation
  3. Lymphocyte-activation gene 3 in cancer immunotherapy: function, prognostic biomarker and therapeutic potentials

Lymphocyte-activation gene 3 in cancer immunotherapy: function, prognostic biomarker and therapeutic potentials

  • Front Immunol. 2024 Nov 26:15:1501613. doi: 10.3389/fimmu.2024.1501613.
Ke Ren 1,  Hayam Hamdy 2,  Abdo Meyiah 1,  Eyad Elkord 1 3 4
Affiliations

Affiliations

  • 1 Department of Biosciences and Bioinformatics, School of Science, Suzhou Municipal Key Lab in Biomedical Sciences and Translational Immunology, Xi'an Jiaotong-Liverpool University, Suzhou, Jiangsu, China.
  • 2 Department of Forensic Medicine and Toxicology, Faculty of Veterinary Medicine, New Valley University, New Valley, Egypt.
  • 3 College of Health Sciences, Abu Dhabi University, Abu Dhabi, United Arab Emirates.
  • 4 Biomedical Research Center, School of Science, Engineering and Environment, University of Salford, Manchester, United Kingdom.
PMID: 39660130 DOI: 10.3389/fimmu.2024.1501613
Abstract

Lymphocyte-activation gene 3 (LAG-3) has emerged as a key Immune Checkpoint regulating immune responses in the context of Cancer. The inhibitory effect of LAG-3-expressing T cells contributes to suppressing anti-tumor immunity and promoting tumor progression. This review discusses the function of LAG-3 in immune suppression, its interactions with ligands, and its potential as a prognostic biomarker for cancers. We also explore therapeutic strategies targeting LAG-3, including monoclonal Antibodies, small molecule inhibitors, and CAR T cells. This review summarizes the current preclinical and clinical studies on LAG-3, highlighting the potential of therapeutic regimens targeting LAG-3 to enhance antitumor immunity and improve patients' outcomes. Further studies are needed to fully elucidate the mechanism of action of LAG-3 and optimize its application in tumor therapy.

Keywords

LAG-3; T cells; biomarker; cancer; immune checkpoint.

Figures